Menke Marcel N, Feke Gilbert T, McMeel J Wallace, Treon Steven P
Schepens Retina Associates Foundation, Boston, Massachusetts 02215, USA.
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1157-60. doi: 10.1167/iovs.07-1254.
Waldenström's macroglobulinemia (WM) is characterized by an overproduction of immunoglobulin M (IgM), which can lead to a hyperviscosity syndrome (HVS) and HVS-related retinopathy. Plasmapheresis is known to reduce serum viscosity (SV) and IgM levels. The purpose of this study was to investigate the effects of plasmapheresis on HVS-related retinopathy and retinal hemodynamic parameters in patients with WM.
Nine patients with HVS due to WM were studied. SV and plasma IgM levels were measured before and after plasmapheresis treatment. The patients were evaluated for HVS-related retinopathy, and hemodynamic changes in a major temporal retinal vein by laser Doppler, before and after plasmapheresis.
Plasmapheresis resulted in significant reductions in serum IgM (46.5% +/- 18.0%, mean +/- SD; P = 0.0009) and SV (44.7% +/- 17.3%, P = 0.002). HVS-related retinopathy improved in all patients after plasmapheresis. After treatment, the venous diameter decreased in each patient by an average of 15.3% +/- 5.8% (P = 0.0001). A significant (P = 0.0004) 55.2% +/- 22.5% increase in retinal venous blood speed accompanied the decreases in diameter. There was no significant change in the retinal blood flow rate after treatment. The percentage decreases in SV in the patients were significantly correlated with the percentage decreases in venous blood column diameter (P = 0.031, R(2) = 0.51).
HVS triggers a distinctive retinopathy with a central retinal vein occlusion (CRVO)-like appearance. However, the retinal blood flow is not decreased as in CRVO, but remains at normal levels. Plasmapheresis is effective in reversing HVS-related retinopathy and in reducing abnormal venous dilatation.
华氏巨球蛋白血症(WM)的特征是免疫球蛋白M(IgM)产生过多,这可导致高黏滞综合征(HVS)及HVS相关的视网膜病变。已知血浆置换可降低血清黏度(SV)和IgM水平。本研究的目的是探讨血浆置换对WM患者HVS相关视网膜病变及视网膜血流动力学参数的影响。
对9例因WM导致HVS的患者进行研究。在血浆置换治疗前后测量SV和血浆IgM水平。在血浆置换前后,对患者进行HVS相关视网膜病变评估,并通过激光多普勒测量视网膜颞侧主要静脉的血流动力学变化。
血浆置换导致血清IgM(46.5%±18.0%,均值±标准差;P = 0.0009)和SV(44.7%±17.3%,P = 0.002)显著降低。血浆置换后所有患者的HVS相关视网膜病变均有改善。治疗后,每位患者的静脉直径平均减小15.3%±5.8%(P = 0.0001)。随着直径减小,视网膜静脉血流速度显著增加(P = 0.0004),增加了55.2%±22.5%。治疗后视网膜血流速率无显著变化。患者SV的降低百分比与静脉血柱直径的降低百分比显著相关(P = 0.031,R² = 0.51)。
HVS引发一种具有视网膜中央静脉阻塞(CRVO)样外观特征的独特视网膜病变。然而,视网膜血流并不像CRVO那样减少,而是保持在正常水平。血浆置换在逆转HVS相关视网膜病变及减少异常静脉扩张方面有效。